680 filings
Page 19 of 34
6-K
ez5sryg3qjg8u4n4zjt0
17 Jan 18
Current report (foreign)
12:00am
6-K
x3kkla54zonjt7
16 Jan 18
RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA® for IBS-D
12:00am
6-K
bjdx 3ij5maer
22 Dec 17
RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA®) for Cholangiocarcinoma at Mayo Clinic and MD Anderson
12:00am
6-K
dab1hs
5 Dec 17
RedHill Biopharma Provides 2017 Year-End Business Update
12:00am
6-K
jk9zyszzxqas
13 Nov 17
RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares
12:00am
6-K
f5jyt4yg
13 Nov 17
Current report (foreign)
12:00am
6-K
7d6 xnpnror
9 Nov 17
Current report (foreign)
12:00am
6-K
p0da3n911x4h8
9 Nov 17
RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease
12:00am
6-K
ih9s83fngi3v698bni
8 Nov 17
RedHill Biopharma Prices Public Offering of its American Depositary Shares
12:00am
6-K
rzpxg dwu3d
7 Nov 17
RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares
12:00am
6-K
u78bfby ays
6 Nov 17
RedHill Biopharma Announces EnteraGam® Poster Presentation at the ISPOR 20th Annual European Congress
12:00am
6-K
cgrllel0iu8m
6 Nov 17
Current report (foreign)
12:00am
6-K
4ijm 0fk5dh01eiz
1 Nov 17
RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines
12:00am
6-K
gtk55bpduwirh1
26 Oct 17
RedHill Biopharma to Present at the BIO-Europe 2017 Conference
12:00am
6-K
3u9fx2t4k1t9mdb
23 Oct 17
RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104
12:00am
6-K
iu72qgflwu7njy
20 Oct 17
RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer
12:00am
6-K
rdl8g35lyx2a6jkx
19 Oct 17
RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
12:00am
6-K
1q3mox54v2p 9cpynnhn
10 Oct 17
RedHill Biopharma to Present at the BioNetwork 2017 Partnering Summit
12:00am
6-K
jkq9nqbmulzob7ovdh
3 Oct 17
Current report (foreign)
12:00am
6-K
d3j3l
2 Oct 17
RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018
12:00am